INTRODUCTION {#s1}
============

*DNM1L* encodes dynamin-related protein 1 (DRP1), an 80-kDa GTPase of the dynamin superfamily. Dynamins play crucial roles in vesicle formation and organelle division; specifically, DRP1 plays a crucial role in mitochondrial and peroxisomal fission (division) as well as mitochondrial trafficking and distribution ([@MCS003673ASSC29]; [@MCS003673ASSC30]; [@MCS003673ASSC39]; [@MCS003673ASSC21]; [@MCS003673ASSC43]). Disruption of mitochondrial dynamics, the balance between mitochondrial fission and fusion, affects mitochondrial integrity ([@MCS003673ASSC4]), leading to neuropathy ([@MCS003673ASSC54]) and neurodegenerative diseases ([@MCS003673ASSC1]; [@MCS003673ASSC32]; [@MCS003673ASSC3]). DRP1 dysfunction has been implicated in mitochondrial disorders and neurodegenerative disorders including Alzheimer\'s, Parkinson\'s, and Huntington\'s diseases ([@MCS003673ASSC44]; [@MCS003673ASSC33]). Indeed, deletion of neural-specific *Drp1* in mice is lethal shortly after birth, resulting in brain hypoplasia, abnormal neurites, and defective synapse formation ([@MCS003673ASSC18]).

DRP1 is recruited to the outer mitochondrial membrane to interact with receptors such as fission protein 1 (FIS1), mitochondrial fission factor (MFF), mitochondrial dynamics protein of 49 kDa (MID49), and mitochondrial dynamics protein of 51 kDa (MID51) ([@MCS003673ASSC4]). In that context, DRP1 acts by forming homodimers that self-assemble into higher-order structures that create a "band" around the mitochondria, which constricts to induce fission ([@MCS003673ASSC39]). Disruption of this process results in fewer, longer, abnormally distributed mitochondria and in peroxisomes ([@MCS003673ASSC30]; [@MCS003673ASSC39]; [@MCS003673ASSC50]; [@MCS003673ASSC21]; [@MCS003673ASSC24]). Studies have implicated *DNM1L* variants in impaired mitochondrial function, including impaired mitochondrial fission, reduced membrane potential, and lower oxidative capacity, resulting in increased cellular levels of reactive oxygen species (ROS) and double-stranded DNA breaks ([@MCS003673ASSC17]).

DRP1 is highly homologous to dynamin proteins, sharing the three major dynamin domains: the GTPase domain, which is conserved, the middle domain, and the GTPase effector domain (GED). Pathogenic variants in model systems affecting all three domains have been shown to ultimately impact the oligomerization and self-assembly of DRP1 ([@MCS003673ASSC31]; [@MCS003673ASSC5]; [@MCS003673ASSC17]). The GTPase domain is also responsible for the conformational change driving the fission process of mitochondria and peroxisomes ([@MCS003673ASSC26]). The GED domain stimulates the GTPase activity and participates in formation and stability of the DRP1 homodimer complex ([@MCS003673ASSC53]).

Pathogenic variants in *DNM1L* are associated with a neurological disorder referred to as encephalopathy due to defective mitochondrial and peroxisomal fission 1 (EMPF1, OMIM \#603850). Affected individuals have variable phenotypes ranging from severe hypotonia leading to death in the neonatal period to developmental delay/regression, with or without seizures. The first patient, described in 2007 ([@MCS003673ASSC48]), was a newborn girl with microcephaly, abnormal brain development, optic atrophy, persistent lactic acidemia, and mildly elevated plasma very long chain fatty acids (VLCFA). Immunofluorescent studies of the patient\'s fibroblasts showed abnormal peroxisomes and mitochondria in a pattern that resembled mammalian cells affected by overexpression of *DNM1L* pathogenic variants or *DNM1L* down-regulation ([@MCS003673ASSC30]; [@MCS003673ASSC39]; [@MCS003673ASSC50]; [@MCS003673ASSC21]; [@MCS003673ASSC24]). This finding led to identification of a novel heterozygous variant in the middle domain of *DNM1L*. For nearly 10 years no other patients were described, but recent studies have dramatically expanded the number of patients and range of phenotypes ([@MCS003673ASSC16]; [@MCS003673ASSC46]). These studies include reports of heterozygous missense variants in the middle domain of *DNM1L* in nine unrelated individuals ([@MCS003673ASSC6]; [@MCS003673ASSC13]; [@MCS003673ASSC38]; [@MCS003673ASSC40]; [@MCS003673ASSC52]; [@MCS003673ASSC8]; [@MCS003673ASSC36]). From model organism studies, the mechanism appears to be dominant negative.

Pathogenic variants in the GTPase domain of *DNM1L* have also been implicated in human disease. Biallelic pathogenic variants (compound heterozygous variants including at least one gene-disrupting allele \[[@MCS003673ASSC28]; [@MCS003673ASSC51]\] and homozygous missense variants \[[@MCS003673ASSC17]\]) in this domain have been associated with a neurological phenotype in five patients from three unrelated families, whereas heterozygous variants were found to segregate in families with autosomal dominant isolated optic atrophy ([@MCS003673ASSC15]). Although the biallelic variants were found to result in loss of function ([@MCS003673ASSC28]; [@MCS003673ASSC51]), functional analysis of the heterozygous variants associated with optic atrophy was suggestive of a restricted dominant negative effect ([@MCS003673ASSC15]; [@MCS003673ASSC16]). To our knowledge, disease-causing variants in the GED domain have never been reported in humans. Here we present a 27-yr-old previously undiagnosed female with severe encephalopathy and disability and a history of seizures and nystagmus. Whole-exome sequencing (WES) identified a novel variant in the GED domain of *DNM1L*, which we study in *Drosophila*.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

The patient is a 27-yr-old female who was evaluated in our Adult Genetics clinic for encephalopathy, disability, and epilepsy ([Fig. 1](#MCS003673ASSF1){ref-type="fig"}A). She was born to nonconsanguineous Caucasian parents ([Fig. 1](#MCS003673ASSF1){ref-type="fig"}B). The pregnancy was reportedly normal, with no history of maternal infections or exposures, unremarkable fetal ultrasounds, and normal fetal movements. She was delivered at term, with a birth weight of 8 lb 2 oz. At birth, she was noted to have hypotonia, but did not require any special care and did not have significant respiratory or feeding difficulties. She was also noted to have nystagmus, and an ophthalmological exam in infancy revealed optic atrophy although her vision remained intact.

![(*A*) The patient at age 27 yr. She is nonverbal and nonambulatory but is able to partially communicate using a communication board. (*B*) Patient\'s pedigree. (*C*) Timeline of clinical symptoms and diagnostic testing. Time is shown on the *x*-axis. Clinical symptoms are depicted *above* the timeline corresponding to time of onset. Duration of symptoms occurring over a period of time is indicated with blue boxes. *Below* the line, diagnostic studies are shown with red arrowheads indicating time of studies. (VLCFA) Very long chain fatty acids, (PAA) plasma amino acids, (UOA) urine organic acids, (ACP) acylcarnitine profile, (CSF) cerebrospinal fluid. Array CGH v5.0 indicates Array Comparative Genomic Hybridization version 5.0. Array CGH v8.1.1 indicates Array Comparative Genomic Hybridization version 8.1.1 (Baylor Genetics). WES (Baylor Genetics).](MCS003673Ass_F1){#MCS003673ASSF1}

At age 3 mo the patient developed unprovoked myoclonic seizures. Workup was unrevealing, and seizures did not recur for several years. The patient had global developmental delay as a child and was later diagnosed with static encephalopathy. She never walked independently but was able to ambulate using a walker at the age of 3. Over time she developed spasticity and became wheelchair-bound. She has also developed spastic quadriparesis and severe scoliosis requiring surgery in her teens. The patient verbally expressed less than five words but was somewhat able to communicate using a picture communication board. Around 12 yr of age, she began to have partial complex seizures, including episodes of status epilepticus, which were refractory to several antiepileptic drugs. At this time, she also developed cyclic vomiting which necessitated hospitalization for rehydration. Repeat EEGs showed background slowing without focal or lateralizing abnormalities and no epileptiform activity. Brain imaging studies including CT and MRI showed some degree of cerebellar atrophy. Seizures were well-controlled at age 20 yr with levetiracetam and lamotrigine, and she has remained seizure-free since. The patient has never had behavioral problems, and her demeanor has always been pleasant. She requires assistance with activities of daily living; she was able to finger-feed herself in the past but has had a general deterioration with reduced energy level in her 20s. Delayed menarche (onset at age 20 yr) was also present. On exam at age 27 yr she was nondysmorphic, visually attentive, and had axial hypertonia with diffuse muscle wasting, spasticity, and brisk deep tendon reflexes bilaterally with clonus.

Differential diagnoses of mitochondrial disease, chromosomal anomaly, neurotransmitter disorder, and *POLG*-related disorders were considered. Extensive metabolic workup over the years, including lactate, pyruvate, VLCFA, plasma amino acids, urine organic acids, acylcarnitine profile, serum creatine/guanidinoacetate, and transferrin isoelectric focusing, was not informative. CSF analysis revealed a slightly decreased level of tetrahydrobiopterin but normal/slightly increased neurotransmitter levels. In this context, it did not seem likely that her symptoms resulted from a neurotransmitter abnormality, and she had a limited response to a trial of carbidopa-levodopa.

Genomic Analyses {#s2b}
----------------

The patient had undergone an extensive prior diagnostic workup since the onset of her symptoms in infancy without any etiologic diagnosis ([Fig. 1](#MCS003673ASSF1){ref-type="fig"}C). Previous genetic testing, including array CGH (version 5.0 and Oligo version 8.1.1, Kleberg Cytogenetics Laboratory), mitochondrial DNA sequencing, and single nuclear gene testing (*MECP2*, *CDKL5*, *SCN1A*, and *POLG*) was unrevealing. WES in 2012 was nondiagnostic; however, reanalysis of WES data in 2017 detected a heterozygous, de novo novel variant in exon 19 of *DNM1L* (NM_012062, Chr 12:32895600; c.2072A\>G, p.Tyr691Cys). This missense variant had not been previously reported as pathogenic and was absent from the gnomAD and ExAC databases ([@MCS003673ASSC23]). The variant substitutes a highly conserved amino acid residue in the GED domain of DRP1, with a combined annotation-dependent depletion score (CADD score) of 28.4 ([Fig. 2](#MCS003673ASSF2){ref-type="fig"}; [@MCS003673ASSC20]). In silico predictions are discordant: "tolerated" by SIFT and "probably damaging" by PolyPhen-2. Although this variant affects the GED domain of the protein and all previous pathogenic de novo events were found to affect the middle domain ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003673/-/DC1)), the variant was classified as "likely pathogenic" by ACMG criteria ([@MCS003673ASSC34]). No other variants in known disease-causing genes that may explain the phenotype were reported ([Table 1](#MCS003673ASSTB1){ref-type="table"}).

![*DNM1L* alleles associated with human disease. (*A*) The *DNM1L* gene encoding the DRP1 protein is shown in schematic. Each mutation is shown at its position on the encoded protein. Shaded arrowheads indicate the zygosity and associated phenotype as seen on the legend. (Red) Heterozygous variants associated with an autosomal dominant neurological disorder. (Dark blue) Compound heterozygous or homozygous variants associated with an autosomal recessive neurological disorder. (Light blue) Heterozygous variants associated with dominant isolated optic atrophy. The red arrow indicates the patient\'s variant (p.Y691C). (EMPF1) Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1. (*B*) Sequence alignment of the amino acid stretch surrounding the *DNM1L*^*Y691C*^ in DNM1L (*Homo sapiens*), ADL2b (*Arabidopsis thaliana*), Vps1p (*Saccharomyces cerevisiae*), and DymA (*Dictyostelium discoideum*). Residues conserved among all four species are shaded in yellow. Residues identical in three out of four species are shaded in blue. GenBank accession numbers: DNM1L, BAA22193; ADL2b, BAB85645; Vps1p, NP_012926; and DymA, CAA67983. Position of the last amino acid in the alignment is indicated. The Y691C variant alters a conserved residue in the GED domain (red arrow). A point mutation in a nearby conserved residue (p.K679A, marked by asterisk) was previously shown to alter the intramolecular association between the GED domain and GTPase domain ([@MCS003673ASSC53]).](MCS003673Ass_F2){#MCS003673ASSF2}

###### 

Carrier status and variants of unknown significance detected on the patient\'s whole-exome sequencing

  Gene         Chromosome   HGVS DNA reference     HGVS protein reference   Variant type   Predicted effect   dbSNP/dbVar ID    Genotype  Parent of origin
  ------------ ------------ ---------------------- ------------------------ -------------- ------------------ ---------------- ---------- ------------------
  *DNM1L*      12           NM_012062:c.2072A\>G   p.Tyr691Cys              Missense       Substitution       N/A                 Het     De novo
  *PPT1*       1            NM_000310:c.635A\>G    p.Asn212Ser              Missense       Substitution       rs568730410         Het     Maternal
  *ADCK3*      1            NM_020247:c.730G\>C    p.Gly244Arg              Missense       Substitution       rs199619932         Het     Maternal
  *NDUFB3*     2            NM_002491:c.19C\>T     p.His7Tyr                Missense       Substitution       rs144513268         Het     Paternal
  *SERPINA1*   14           NM_000295:c.1096G\>A   p.Glu366Lys              Missense       Substitution       rs28929474          Het     Paternal

(AR) autosomal recessive, (Het) heterozygous, (N/A) not applicable.

Metabolic Profiling {#s2c}
-------------------

Given that *DNM1L* is associated with changes in mitochondrial and peroxisomal dynamics, we searched for clinical evidence of mitochondrial or peroxisomal dysfunction. Notably, previously reported *DNM1L* cases have not consistently shown defects in plasma VLCFA nor elevated lactate ([Table 2](#MCS003673ASSTB2){ref-type="table"}). Nevertheless, we sought to find whether the patient has any biochemical abnormalities that indicate perturbations of these functions. We applied global metabolomic profiling through Baylor Genetics Laboratories ([@MCS003673ASSC27]; [@MCS003673ASSC19]), which is a biochemical small-molecule metabolic profile analysis that was recently utilized to establish a biochemical profile of patients with peroxisomal disorders ([@MCS003673ASSC47]). Analysis of biochemical analytes from the patient\'s plasma did not reveal any obvious overlap between the analytes that are characteristically altered in peroxisome biogenesis disorders and the patient\'s sample ([Supplemental Table 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003673/-/DC1)). However, the characteristic metabolite changes associated with peroxisomal disorders are known to attenuate with age. Moreover, the patient had previously had normal VLCFA analysis. Therefore, we were unable to functionally validate the pathogenicity of the *DNM1L* variant in the clinic and functional studies in a model organism were needed.

###### 

Clinical spectrum of *DNM1L*-related disorders

                       GTPase domain   Middle domain   GED domain                                                                                                                                                                 
  ------------------- --------------- --------------- ------------ -------- ------- -------------------- ------- ------ ----------------------- -------- ------ -------- -------- ------------------------- ------- ------------- -------
  Onset                   \<10 yr          1 yr           1 yr      Birth    Birth   1st months of life    NR     5 mo          \<6 mo           \<6 mo   6 d     4 yr     5 yr            \<18 mo           6 mo       3 mo       Birth
  Hypotonia                 NR              \-             \-        +++      +++            \+            NR      \+    Head control at 18 mo     \+     +++      \-       \-               NR               +++        \-         \+
  Dev. delay                \-              \+             \+        N/A      N/A            \+            \-      \+             \+               \+      \+      \+       \+               \+               \+         \+         \+
  Dev. regression           \-              \-             \-        N/A      N/A            \+            \-      \+             \-               \-     N/A      \+       \+     \+ Progressive dystonia    \-         \+         \+
  Seizures                  \-              \-             \-         \-      \-             NR            \-     +SE            \+ SE             \-      \-    \+ SE    \+ SE              +SE             \+ IS   Tremor, HRS   \+ SE
  Optic atrophy             \+              \-             NR         \-      \-             NR            \+      \-             NR               \-      \+      NR       NR               \-               NR         NR         \+
  Nystagmus                 NR          Strabismus     Strabismus     NR      NR             NR            NR      \+             NR               NR      \+      NR       NR               NR               \+         OGC        \+
  Abnormal MRI              \-              \-             NR         \-      HI             \+            \-      \+             \-               \+      \+      \+       \+               \+               \+         \+         \-
  Increased lactate         NR              \+             \-       On MRS    NR        Intermittent       NR      \+             \-               \+      \+      \-     On MRS           On MRS             \+         \+         \-
  Abnormal VLCFA            NR              \-             \-         \-      NR             \-            NR      \-             \-               \-      \+      \-       \-               \-               NR         NR         \-
  Mito. abnorm.             \+              \+             \+         \+      \+             \+            \+      \+             \+               \+      \+      \+       \+               \+               \+         \+         \+
  Peroxi. abnorm.           \-              \+             \+         NR      NR             \-            \-      \+             NR               \-      \+      NR       NR               NR               \+         \+         \+
  Survival                 Adult          \>16 yr        \>3 yr      3 wk     8 d          \>4 yr         Adult   5 yr          \>7 yr           \>2 yr   37 d   \>8 yr   \>7 yr            13 yr            18 mo     2.5 yr      Adult

(CSF) cerebrospinal fluid, (HI) hypoxic-ischemic insult, (HRS) hypokinetic-rigid syndrome, (IS) infantile spasms, (Mito. abnorm.) mitochondrial abnormalities (defined as abnormal shape, distribution, or functional abnormalities in patients or model systems), (mo) months, (MRS) magnetic resonance spectroscopy, (N/A) not applicable, (NR) not reported, (OGC) oculogyric crisis, (Peroxi. abnorm.) peroxisomal abnormalities (defined as abnormal shape, distribution, or functional abnormalities in patients or model systems), (SE) status epilepticus, (yr) year, (+++) severe phenotype.

Peroxisomal Morphology Studies in *Drosophila melanogaster* {#s2d}
-----------------------------------------------------------

To functionally assess the effect of the patient\'s variant on peroxisomes and mitochondria, we undertook a study in *Drosophila melanogaster*. *Drosophila drp1* is the closest homolog of *DNM1L*. *Drosophila drp1* (*drp1*^*1*^/*drp1*^*2*^) mutants are lethal, with impaired mitochondrial trafﬁcking to synapses, mitochondrial morphology, and synaptic transmission ([@MCS003673ASSC42]). Previously, we demonstrated that a middle domain variant of *DNM1L*, p.G350R, identified in a 14-mo-old male with global developmental delay and seizures, failed to rescue fly *drp1* mutants. Overexpression of this variant impaired mitochondrial trafficking and altered mitochondrial and peroxisomal morphology ([@MCS003673ASSC6]). We engineered the p.Y691C variant found in our patient into a codon-optimized human *DNM1L* construct and generated transgenic flies carrying the human *DNM1L* gene with and without the patient\'s variant. We compared the effect of the p.Y691C variant (*DNM1L*^*Y691C*^) to that of the p.G350R variant (*DNM1L*^*G350R*^) that we previously studied with this system ([Fig. 3](#MCS003673ASSF3){ref-type="fig"}A,B; [@MCS003673ASSC6]). In addition, we generated another control construct that deleted the GED domain entirely (*DNM1L*^*ΔGED*^). The *DNM1L*^*ΔGED*^ construct was generated in order to test whether specific deletion of this domain in *Drosophila* also results in lethality or alters peroxisomal morphology.

![Functional studies in *Drosophila melanogaster*. (*A*) Table of rescue crosses showing lethality rescue results for *drp1* mutants expressing the constructs shown. (*B*) Schematic of the constructs and the location of the mutations in the *DNM1L* domains. (*C*--*F*) Dominant effects of DNM1L expression on *Drosophila* salivary gland peroxisomes. (*C***--***C′′*) *Drosophila* salivary gland cells are shown with expression of the reference *DNM1L* with Actin-GAL4 alongside UAS-EGFP-SKL ([@MCS003673ASSC6]) and costained with *Drosophila* anti-Pex3 antibody. (*D*--*D*′′) Middle domain variant p.G350R ([@MCS003673ASSC6]) produces enlarged peroxisomes with abnormal distribution. Fewer peroxisomes are apparent in the cell. (*E*--*E*′′) GED domain variant p.Y691C (seen in the patient) produces enlarged peroxisomes with abnormal distribution, and fewer peroxisomes are apparent in the cell, similar to p.G350R. (*F*--*F*′′) *DNM1L*^*ΔGED*^ construct does not appear to have a dramatic effect on peroxisomal size as well as number of peroxisomes per sample as compared with *DNM1L*^*Ref*^. (*G*) Quantification of the peroxisomal area per peroxisome (µm^2^). (*H*) Quantification of number of peroxisomes per sample.](MCS003673Ass_F3){#MCS003673ASSF3}

*DNM1L*^*Y691C*^ Fails to Rescue *Drosophila drp1* Mutants {#s2e}
----------------------------------------------------------

To demonstrate that the human reference sequence construct (*DNM1L*^*Ref*^) was able to rescue a *drp1* ﬂy mutant (*drp1*^*1*^/*drp1*^*2*^), we crossed the transgenes into *drp1* backgrounds. By expressing human *DNM1L*^*Ref*^ ubiquitously with Da-GAL4, we rescued the lethality of *drp1* mutants ([Fig. 3](#MCS003673ASSF3){ref-type="fig"}A; [Supplemental Fig. 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003673/-/DC1); [Supplemental Table 3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003673/-/DC1)). As expected, the *DNM1L*^*G350R*^ construct from the previously reported case did not rescue lethality. The *DNM1L*^*Y691C*^ construct also did not rescue lethality although we did observe some escapers. Interestingly, the *DNM1L*^*ΔGED*^ led to partial rescue with dramatically reduced Mendelian ratios.

Overexpression of *DNM1L*^*Y691C*^, but Not Deletion of the GED Domain, Results in Peroxisomal Abnormalities {#s2f}
------------------------------------------------------------------------------------------------------------

To study the effect of *DNM1L*^*Y691C*^ on peroxisomes, the fly transgenic lines were crossed to an Actin-GAL4, UAS-GFP-SKL peroxisomal marker line as previously described ([@MCS003673ASSC47]). We observed larger peroxisomal size and perinuclear distribution of the peroxisomes in salivary glands of both the *DNM1L*^*Y691*^ and *DNM1L*^*G350R*^ mutants. Overexpression of the wild-type protein did not affect peroxisomal morphology ([Fig. 3](#MCS003673ASSF3){ref-type="fig"}C--H). Finally, to determine whether the effect of the p.Y691C variant was due to loss of the GED domain or a dominant negative effect, we overexpressed the *DNM1*^*ΔGED*^ in salivary glands of *Drosophila* larvae. Interestingly, these mutants did not exhibit the perinuclear distribution or the large organelle size as in the *DNM1L*^*Y691*^ and *DNM1L*^*G350R*^ mutants ([Fig. 3](#MCS003673ASSF3){ref-type="fig"}C--H), arguing against loss of function as a mechanism for this phenotype. We did test the expression levels in all the different constructs using quantitative PCR. We saw no striking differences; there was a mild relatively higher expression level in the *DNM1L*^*Ref*^ compared to the other three constructs ([Supplemental Fig. 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003673/-/DC1); [Supplemental Table 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003673/-/DC1)).

Overexpression of *DNM1L*^*Y691C*^ Causes Mitochondrial Morphology Aberration {#s2g}
-----------------------------------------------------------------------------

In the lethality rescue assay we had observed mild differences between the *DNM1L*^*Y691C*^ and the previously studied *DNM1L*^*G350R*^, suggesting our patient\'s GED domain missense allele might be milder than the middle domain alleles; however, the peroxisomal studies showed no difference between these, suggesting both alleles had strong dominant negative impact on peroxisome morphology. We hypothesized that the difference in lethality rescue therefore might be due to a different effect of *DNM1L*^*Y691C*^ on mitochondrial fission. Indeed, a recent report of missense, dominant negative GTPase alleles showed a differential impact on mitochondria without a significant peroxisomal impact ([@MCS003673ASSC15]). *DNM1L* has a well-established impact on mitochondrial fission observed in the middle domain alleles ([@MCS003673ASSC6]). We therefore tested mitochondrial morphology in transgenic fly lines of *DNM1L*^*Ref*^ versus *DNM1L*^*Y691C*^. These were crossed with MEF2-GAL4 in a sensitized genetic background (*drp1*^*1*^/+). We noticed a dramatic change in muscle mitochondrial morphology ([Fig. 4](#MCS003673ASSF4){ref-type="fig"}A,B) and distribution ([Fig. 4](#MCS003673ASSF4){ref-type="fig"}C,D). *DNM1L*^*Y691C*^ transgenics displayed a network of mitochondria near the muscle perinuclear region ([Fig. 4](#MCS003673ASSF4){ref-type="fig"}E) with a scarcity of mitochondria in muscle fibers as compared with *DNM1L*^*Ref*^ ([Fig. 4](#MCS003673ASSF4){ref-type="fig"}F). This effect was very similar to the effect of middle domain variants *DNM1L*^*G350R*^ and *DNM1L*^*A395D*^ we have previously shown ([@MCS003673ASSC6]). Therefore, we observed a similar impact of the *DNM1L*^*Y691C*^ allele on mitochondria as observed on peroxisomes suggesting a dominant negative allele.

![Functional studies in *Drosophila melanogaster* third-instar larval muscle fibers. (*A*) A perinuclear section of a muscle fiber from the UAS-*DNM1L*^*Ref*^ crossed to MEF2-GAL4 in a sensitized genetic background (*drp1*^*1*^/+) stained with anticomplex V antibody showing a pattern of normal mitochondrial morphology. (*A*′) *Inset* of *A*. (*B*) A perinuclear section of a muscle fiber from the UAS-*DNM1L*^*Y691C*^ stained with anticomplex V antibody crossed to MEF2-GAL4 showing an abnormal interconnected mass of mitochondrial staining without clear delineating between individual organelles. (*B*′) *Inset* of *B*. (*C*) A deep muscle fiber section stained with phalloidin and anticomplex V from the UAS-*DNM1L*^*Ref*^ crossed to MEF2-GAL4 showing a normal distribution of mitochondria between the sarcomeres. (*C*′) The same section as *C* without phalloidin staining shown. (*D*) A deep muscle fiber section stained with phalloidin and anticomplex V of from the UAS-*DNM1L*^*Y691C*^ crossed to MEF2-GAL4 showing a paucity of mitochondria between the sarcomeres. (*D*′) The same section as *D* without phalloidin staining shown. (*E*) Quantification of numbers of separate mitochondria per micrometer from the perinuclear region; five animals per genotype were quantified. (*F*) Quantification of the number of mitochondria per sarcomere in deep fiber sections; five animals per genotype were quantified.](MCS003673Ass_F4){#MCS003673ASSF4}

DISCUSSION {#s3}
==========

Here, we describe an adult patient with a unique phenotype due to a *DNM1L* GED domain de novo variant. We use *Drosophila* models to show that this p.Y691C variant fails to rescue *Drosophila drp1* lethality and it results in a strikingly abnormal peroxisomal phenotype, with abnormally shaped peroxisomes in irregular distribution, likely consistent with a dominant negative effect ([Fig. 3](#MCS003673ASSF3){ref-type="fig"}C--F). Our previous studies in *Drosophila* on *DNM1L* also included the p.A395D allele, which had been shown to display dominant negative effects in other assays. Based on this we had confidence in our assay for identifying these effects in this novel mutation. To our knowledge, this is the first report of a pathogenic variant in this domain associated with disease in humans.

Previous reports of pathogenic variants in *DNM1L* associated with a neurological phenotype (EMPF1) include heterozygous variants in the *DNM1L* middle domain with experimentally confirmed or putative dominant negative effects ([@MCS003673ASSC48]; [@MCS003673ASSC6]; [@MCS003673ASSC13]; [@MCS003673ASSC38]; [@MCS003673ASSC40]; [@MCS003673ASSC52]) and biallelic variants (compound heterozygous \[[@MCS003673ASSC28]; [@MCS003673ASSC51]\] and homozygous \[[@MCS003673ASSC17]\] variants) in the GTPase domain with a strong loss-of-function mechanism. All the biallelic variants reported have been inherited from reportedly unaffected parents, indicating that haploinsufficiency was not a significant factor for these variants ([@MCS003673ASSC16]). Interestingly, heterozygous variants in the GTPase domain result in familial isolated optic atrophy. Results of the functional analysis of these variants also suggest a dominant negative mechanism ([@MCS003673ASSC15], [@MCS003673ASSC16]). In that case there was a specific effect on mitochondria without a peroxisomal effect. In our study of this GED domain variant, we observe that both organelles are affected. This is consistent with the overall similarity of our patient\'s clinical phenotypes compared to some of the patients with reported middle domain variants, whereas the dominant GTPase alleles appear to lead to optic atrophy.

The *DNM1L*^*Y691C*^ variant appears to resemble the effect of middle domain variants like *DNM1L*^*G350R*^ with respect to both peroxisomal and mitochondrial morphology, although the rescue data suggests it may be a milder allele. Deletion of the GED domain led to a partial loss of function in lethality rescue assays and no dominant negative effect. These data suggest a dominant negative mechanism for the *DNM1L*^*Y691C*^ rather than the loss of GED function. The GED domain plays a role in activation of the GTPase domain. Interestingly, we find that the GED domain is somewhat dispensable (as the truncated protein is still somewhat able to rescue lethality in *drp1* flies). The mechanism by which variants in the GED domain have a dominant negative impact is unclear. One possibility is that the *DNM1L*^*Y691C*^ impairs interaction with other *DNM1L* monomers. Alternatively, the impact could be on the GTPase function indirectly because of the GED associating with the GTPase domain intramolecularly. In support of this, the function of the GED was studied in yeast through investigation of mutant Drp1 harboring a p.K679A mutation ([@MCS003673ASSC53]). The mutant protein had a weaker intramolecular association resulting in impaired GTPase activity, despite unaffected Drp1 complex formation. Interestingly, the amino acid altered in that experiment lies very close to the missense change in our patient ([Fig. 2](#MCS003673ASSF2){ref-type="fig"}). Additional structural modeling could clarify this interaction.

The patient we present represents the first report of an adult with a pathogenic *DNM1L* variant resulting in a neurological phenotype. The neurological disorder associated with *DNM1L* is currently termed "EMPF1" and described as a lethal encephalopathy. However, although three cases resulted in death in the neonatal period ([@MCS003673ASSC48]; [@MCS003673ASSC51]) and three other patients died an early death at 18 mo ([@MCS003673ASSC52]), 2.5 yr ([@MCS003673ASSC8]), and 5 yr ([@MCS003673ASSC6]), other individuals with *DNM1L* pathogenic variants were not critically ill. The majority of the patients presented in the newborn period with hypotonia or later in the first year of life with developmental delay. Two patients had significant developmental regression following apparently normal initial development ([@MCS003673ASSC8]; [@MCS003673ASSC17]). Neurological findings were variable and included spasticity and hyperreflexia, ataxia with pyramidal signs, dystonia, and even parkinsonism. Others presented with optic atrophy alone. Our patient (also diagnosed with optic atrophy) presented with neonatal hypotonia progressing to spasticity, developmental delays, and static encephalopathy and survived to adulthood. Her history of transient cyclic vomiting, which is considered a childhood variant of migraine ([@MCS003673ASSC35]), may also be an associated phenotypic feature as altered mitochondrial dynamics and elevated levels of Drp1 have been observed in a rat model of migraine ([@MCS003673ASSC9]). Taken together, this highlights the wide spectrum and variability of the neurological phenotypes associated with this disorder (see [Table 2](#MCS003673ASSTB2){ref-type="table"} for the clinical spectrum of *DNM1L*-related disorders and [Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003673/-/DC1) for a table of variants).

Given the small number of patients reported to date and the variability of the presentations, genotype--phenotype correlations are difficult to determine. Our patient\'s attenuated phenotype possibly results from the deleterious effect of the variant on the function of the GED domain, which may differ from the effects of pathogenic variants in the GTPase and middle domains. Some genotype--phenotype correlation for *DNM1L* may be evidenced by the fact that all three patients reported in the literature with the p.R403C variant presented in childhood (ages 4, 5, and 13 yr) with acute onset of myoclonus and refractory status epilepticus subsequently leading to brain atrophy and death in one patient and severe neurological outcome in the others. Two of these patients had some expressive developmental delays prior to the onset of seizures, one of which also had fine motor delays, anxiety, and progressive paroxysmal dystonia ([@MCS003673ASSC13]; [@MCS003673ASSC36]). Out of the 16 reported cases in the literature, three occurred in p.R403 and one in p.L406 (a nearby residue), suggesting this may represent a mutational hotspot. Similarly, two distinct alleles have been reported impacting p.G362.

In summary, we describe here a patient with a novel, de novo heterozygous variant in the GED domain of the protein encoded by *DNM1L*, which plays an essential role in mitochondrial and peroxisomal dynamics. Functional studies in fly models support a dominant negative mechanism of action for this variant. Given that to date there are no other reports of variants in the GED domain associated with disease in humans, the impact of this domain remains to be explored further. To the best of our knowledge, this is the first report of a *DNM1L* variant in an adult patient with a neurodevelopmental phenotype, expanding the clinical spectrum of *DNM1L*-related disorders. We conclude that "*DNM1L*-related disorders" comprise a broad range of phenotypes associated with different variations in this gene.

METHODS {#s4}
=======

Clinical Cases and Ethics Statement {#s4a}
-----------------------------------

The patient was enrolled in an IRB-approved human study at Baylor College of Medicine under the Biochemistry and Cell Biology Correlates of Peroxisomal Disorders (H-32837), and her parents provided consent for publication of photos and their clinical data. The clinical workup and sequencing was performed as part of standard clinical care.

Whole-Exome Sequencing {#s4b}
----------------------

The patient underwent clinical WES through the Baylor Genetics clinical laboratory using standard methods. DNA was isolated from patient\'s peripheral blood. The next-generation sequencing (NGS) library was constructed on Covaris sonicator--fragmented DNA followed by end repair (NEB E6050L), A-tailing (NEB E6053L), and ligation (Invitrogen A13726101) with Illumina paired-end adaptors (unique index sequences) using 1 µg of genomic DNA input. PCR was performed on the samples using the KAPA master mix (KAPA Biosystem KK2612) and primers compatible with Illumina barcode sequences.

The samples were hybridized using Roche NimbleGen developed solution--based capture protocol and before incubation index sequencing was blocked by universal blocking Oligos P5 (IDT 1016184) and P7 (IDT 1016186). Samples were hybridized using VCRome 2.1 and Spike-in PKv2 probes (lab developed) from 16 to 72 h in a thermocycler at recommended temperature, and uncaptured DNA sequenced washed away using Roche hyb wash reagents. The paired-end single-index run was performed on the Illumina HiSeq 2500 or 2000 platform to obtain average base-pair coverage of \>100 with minimal 20× coverage at 95% of targeted sequences ([Supplemental Table 5](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003673/-/DC1)). The raw sequencing BCL files were converted to FASTQ file using Illumina CASAVA software version 1.8.3. Raw data were demultiplexed and aligned to human genome reference sequence hg19, and a lab-developed software program was used for variant calling and annotation. The variant classification and interpretation were conducted by a clinical standard based on the American College of Medical Genetics and Genomics variant interpretation guidelines.

Exome reanalysis was performed by systematically reevaluating the variants using an updated knowledge base (P Liu, L Meng, EA Normand, et al., in prep.). Candidate variants were PCR-amplified and Sanger-sequenced with both the proband and the parental samples.

Metabolic Profile Analysis {#s4c}
--------------------------

Metabolomic profiling was performed by Baylor Genetics Laboratories and Metabolon, as described previously ([@MCS003673ASSC11], [@MCS003673ASSC12]; [@MCS003673ASSC27]; [@MCS003673ASSC19]). Metabolites were identified by matching the ion chromatographic retention index, accurate mass, and mass spectral fragmentation signatures with a reference library consisting of more than 4000 entries from standard metabolites ([@MCS003673ASSC7]). Metabolite *z*-scores were generated using the method previously described ([@MCS003673ASSC27]; [@MCS003673ASSC10]).

*Drosophila* Transgenics {#s4d}
------------------------

We had previously generated transgenic flies with human DNM1L Reference and a p.G350R variant ([@MCS003673ASSC6]) (DNM1LRef and DNM1LG350R, respectively). We produced human *DNM1L* p.Y691C variant (*DNM1L*^*Y691C*^) and a GED domain deletion construct (*GED*^*ΔGED*^), which were codon-optimized for *Drosophila* expression (GeneArt). These constructs were subcloned into the pUAST-attB vector. Transgenic flies were produced by injecting prepared DNA into VK00033 embryos ([@MCS003673ASSC2]), and the site for site-specific integration was (y\[1\] w\[1118\]; PBac\[y\[+\]-attP-3B\]VK00033) ([@MCS003673ASSC41]).

*Drosophila* Genetics {#s4e}
---------------------

The *drp1*^*1*^ and *drp1*^*2*^ alleles used in this study were reported by [@MCS003673ASSC42]. Transgenic *DNM1L* flies were obtained by crossing into these genetic backgrounds.

Peroxisomal Morphology Studies {#s4f}
------------------------------

Two peroxisomal reporters were used in third-instar larval salivary gland, a UAS-GFP-SKL construct generated by subcloning a carboxy-terminal SKL tagged GFP into the UAS vector and a transgenic insertion on second chromosome was recombined with Actin-GAL4 (y1 w\*; P{Act5C-GAL4}25FO1/CyO, y+) ([@MCS003673ASSC45]). Pex3 staining was performed as described ([@MCS003673ASSC14]). Confocal images were quantified using ImageJ software.

Mitochondrial Morphology Studies {#s4g}
--------------------------------

Transgenic flies with UAS-*DNM1L*^*Ref*^ or UAS-*DNM1L*^*Y691C*^ constructs were crossed with MEF2-GAL4 in a *drp1*^*1*^ mutant background. Third-instar larval muscles were fixed, permeablilized, and stained with primary mouse anticomplex V antibody (abcam 14748), which was then incubated with secondary anti-mouse-Alexa 488 antibody. The muscles were also stained with antiphalloidin conjugated with Alexa 546 and DAPI. Images were captured for ventral longitudinal muscle 6 and 7 from segment A3 using confocal microscope (Zeiss LSM 880). Image analysis was done using ImageJ software.

mRNA Expression Analysis {#s4h}
------------------------

Reverse transcriptase-quantitative PCR (RT-qPCR) was carried out on all the four *DNM1L* flies to assess relative mRNA expression levels among the four genotypic flies. Two biological replicates of 30 adult fly heads were sampled per genotype. Total RNA was isolated from head portions of third-instar larvae that contained salivary glands. Total RNA was extracted from each biological replicate using Triazol RNA isolation. Reverse transcription of total RNA to get cDNA was done using iScript Reverse Transcription Supermix for RT-qPCR (Bio-Rad Laboratories) according to the manufacturer\'s instructions. Equal quantities of this cDNA from each genotype were used to set RT-qPCR reactions for corresponding putative target mRNA transcripts using iQ SYBR Green Supermix (2×) (Bio-Rad Laboratories). All amplification reactions were performed in Bio Rad CFX96 Real-Time PCR Machine (Bio-Rad Laboratories) with three technical replicates across all biological replicates. Normalized mRNA expression levels were calculated using the 2^−ΔΔC(t)^ method ([@MCS003673ASSC37]) with the internal reference as Rpl32.

Note Added in Proof {#s05a}
===================

Since the submission of this manuscript, three additional reports of *DNM1L* variants in children with epilepsy and a range of neurological phenotypes have been published ([@MCS003673ASSC22]; [@MCS003673ASSC49]; [@MCS003673ASSC25]).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

All the relevant data are included in the manuscript and supplemental materials; the *DNM1L* variant has been submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession number SCV000882867. Patient consent for deposition of raw sequencing data was not obtained.

Ethics Statement {#s5b}
----------------

The patient was enrolled in an IRB-approved human study at Baylor College of Medicine (Houston, TX) under the Biochemistry and Cell Biology Correlates of Peroxisomal Disorders (H-32837) and consented for publication of photos and their clinical data.

Acknowledgments {#s5c}
---------------

The authors would like to thank the family for participating in the study. We thank Yu-Hsin Chao for technical support in the design of the *DNM1L* constructs used in this study. We thank Jonathan Andrews for technical advice in the expression analysis.

Author Contributions {#s5d}
--------------------

N.A.B. provided conceptual design, clinical evaluation, and wrote the manuscript. P.K.B. conducted fly experiments. T.N.E. and A.M.G. provided clinical evaluation. P.L. and C.M.E. provided genomic analysis. S.H.E. provided metabolomic analysis. L.A.R. and F.S. provided conceptual design. S.U.D. provided conceptual design and clinical evaluation. M.F.W. provided conceptual design, conducted fly experiments, and wrote the manuscript.

Competing Interest Statement {#s5e}
----------------------------

Fernando Scaglia receives research support from BioElectron Technologies, Reata Pharmaceuticals, and Stealth BioTherapeutics.

Supplementary Material
======================

###### Supplemental Material

\[Supplemental material is available for this article.\]

[^1]: These authors contributed equally to this work.
